Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C. Kollmannsberger C, et al. Among authors: quietzsch d. Br J Cancer. 2000 Aug;83(4):458-62. doi: 10.1054/bjoc.2000.1295. Br J Cancer. 2000. PMID: 10945491 Free PMC article. Clinical Trial.
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C. Honecker F, et al. Among authors: quietzsch d. Anticancer Drugs. 2002 Jun;13(5):497-503. doi: 10.1097/00001813-200206000-00008. Anticancer Drugs. 2002. PMID: 12045461 Clinical Trial.
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.
Hartmann JT, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Köhne CH, Käfer G, Kanz L, Bokemeyer C. Hartmann JT, et al. Among authors: quietzsch d. Br J Cancer. 2003 Dec 1;89(11):2051-6. doi: 10.1038/sj.bjc.6601412. Br J Cancer. 2003. PMID: 14647137 Free PMC article. Clinical Trial.
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
Modest DP, Schulz C, von Weikersthal LF, Quietzsch D, von Einem JC, Schalhorn A, Vehling-Kaiser U, Laubender RP, Giessen C, Stintzing S, Heinemann V. Modest DP, et al. Among authors: quietzsch d. Anticancer Drugs. 2014 Feb;25(2):212-8. doi: 10.1097/CAD.0000000000000041. Anticancer Drugs. 2014. PMID: 24201305 Clinical Trial.
35 results